OLANZAPINE TEVA ® 15 MG

País: Israel

Língua: inglês

Origem: Ministry of Health

Ingredientes ativos:

OLANZAPINE 15 MG

Disponível em:

SALOMON,LEVIN & ELSTEIN LTD

Código ATC:

N05AH03

Forma farmacêutica:

FILM COATED TABLETS

Via de administração:

PER OS

Fabricado por:

TEVA OPERATIONS POLAND SP.ZO.O

Grupo terapêutico:

OLANZAPINE

Indicações terapêuticas:

Acute and maintenance treatment of schizophrenia. Olanzapine Teva® is indicated for the management of the manifestations of psychotic disorders. Olanzapine Teva® is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.Prevention of recurrence in Bipolar Disorder: In patients whose manic episode has responded to olanzapine treatment Olanzapine Teva® is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder. The combination of Olanzapine Teva® with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.

Data de autorização:

2011-04-01